June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Mario Balsa Shares ASCENT-04 Trial Results in First-Line mTNBC at ASCO25
Jun 3, 2025, 10:35

Mario Balsa Shares ASCENT-04 Trial Results in First-Line mTNBC at ASCO25

Mario Balsa, Medical Oncology resident at ICO, shared a post on X:

Breaking from ASCO25 — ASCENT-04 SG + pembro shines in 1L PD-L1+ (CPS ≥10) mTNBC:
  • Median PFS: 11.2 vs 7.8 mo (HR: 0.65, p<0.001).
  • Median DOR: 16.5 vs 9.2 mo.
  • ORR: 60% vs 53%, with more CRs (13% vs 8%) .
A paradigm shift in 1L mTNBC? Sis boom bah!”

Mario Balsa shared key findings from the ASCENT-04 trial at ASCO25, showing that sacituzumab govitecan plus pembrolizumab significantly improved progression-free survival, duration of response, and overall response rate in PD-L1+ first-line metastatic triple-negative breast cancer (mTNBC).

Mario Balsa Shares ASCENT-04 Trial Results in First-Line mTNBC at ASCO25

More posts featuring Mario Balsa.